Skip to main content
Merck, Isomorphic Labs launch AI drug discovery deal
Image for illustrative purposes only. Not a real photo.

Merck, Isomorphic Labs launch AI drug discovery deal

By

Key points

  • Merck (NYSE:MRK) signed a research collaboration with Isomorphic Labs to discover small-molecule drug candidates targeting an oncology indication.
  • Isomorphic Labs will use its AI-powered drug design engine and Merck's proprietary data to develop molecular designs.
  • Merck will handle preclinical and clinical development, manufacturing and commercialization, while Isomorphic Labs will receive upfront, milestone and royalty payments.

Merck (NYSE:MRK) entered a research collaboration with Isomorphic Labs to discover small-molecule drug candidates targeting an oncology target, combining artificial intelligence technology with Merck's proprietary research data.

The partnership brings together Isomorphic Labs' artificial intelligence-based drug discovery capabilities and Merck's pharmaceutical research expertise, with the programme focused on designing potential treatments for cancer.

"The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions," said Merck Research Laboratories Senior Vice President and Head of Discovery, Preclinical Development and Translational Medicine George Addona.

Under the agreement, Isomorphic Labs will use its proprietary Drug Design Engine (IsoDDE) and selected Merck datasets to produce molecular designs, while Merck will oversee preclinical and clinical development, manufacturing and commercialization.

Isomorphic Labs will receive an upfront payment, research, development, regulatory and commercial milestone payments, and tiered royalties on net sales, with an option to co-fund development in exchange for higher royalties.

The collaboration expands the use of AI in pharmaceutical research, with Isomorphic Labs applying computational drug design technology and Merck contributing proprietary datasets and development capabilities to identify potential oncology treatments.


Frequently asked questions